Sangamo Therapeutics: latest news - GoINPHARMA
Tuesday, 25 September 2018 - 0:56

Sangamo Therapeutics

Gilead surprises markets again: signed $3bn agreement with Sangamo

Gilead surprised markets again today as it announced, before Wall Street opened, it has entered into an agreement with Sangamo Therapeutics. The deal grants the California-based company access to Sangamo’s “zinc finger nuclease” technology platform for the development of novel…

Pfizer signs $160m cooperation agreement with Sangamo Therapeutics

Pfizer and Sangamo Therapeutics have announced a cooperation aimed at using the “zinc finger therapy” for the treatment of ALS linked to mutations of the C9ORF72 gene. Thanks to the agreement, Sangamo will receive $12m from Pfizer, plus a potential…